Pulmaquin failure halves Aradigm's value

2 December 2016
aradigm-1-

The share price of USA-based Aradigm (Nasdaq: ARDM) collapsed on Thursday after the company announced top-line results from its two Phase III trials of Pulmaquin (ciprofloxacin).

Pulmaquin is Aradigm’s investigational proprietary formulation of once-daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis (non-CF BE) with chronic lung infections with Pseudomonas aeruginosa (P aeruginosa).

In 2013, Aradigm granted an exclusive, worldwide license for the company's inhaled liposomal ciprofloxacin product candidates for the indication of non-CF BE and other indications to Grifols (GRF: MC), and the Spanish drugmaker's share price had also dropped by nearly 4% by Friday afternoon compared to its closing price on Wednesday, following the announcement of the trial results.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical